Imiquimod 3.75% for field‐directed therapy of actinic keratosis: results of a prospective case‐series study in Greece

BACKGROUND: Imiquimod 3.75% is a field‐directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun‐exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (L (...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Dermatol
Asıl Yazarlar: Befon, Angeliki, Tzanetakou, Vassiliki, Panagiotopoulos, Antonios, Chasapi, Vasiliki, Antoniou, Christina, Stratigos, Alexander J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6850341/
https://ncbi.nlm.nih.gov/pubmed/30779341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijd.14397
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller